**Results: SY-5609 Single Agent**

Single-agent dose escalation: Study summary

<table>
<thead>
<tr>
<th>Dose Level (mg)</th>
<th>Syros-5609 dose (mg)</th>
<th>Number of patients</th>
<th>Dose intensity (mg/kg)</th>
<th>Dose intensity (mg/m²)</th>
<th>B胆 (mg/m²)</th>
</tr>
</thead>
<tbody>
<tr>
<td>2</td>
<td>2</td>
<td>10</td>
<td>0.2</td>
<td>4</td>
<td>4</td>
</tr>
<tr>
<td>5</td>
<td>5</td>
<td>10</td>
<td>0.5</td>
<td>10</td>
<td>10</td>
</tr>
<tr>
<td>10</td>
<td>7</td>
<td>10</td>
<td>0.7</td>
<td>14</td>
<td>14</td>
</tr>
<tr>
<td>15</td>
<td>9</td>
<td>10</td>
<td>0.9</td>
<td>18</td>
<td>18</td>
</tr>
<tr>
<td>20</td>
<td>10</td>
<td>10</td>
<td>1.0</td>
<td>20</td>
<td>20</td>
</tr>
</tbody>
</table>

No DLTs reported

**Results: SY-5609 + Gem + Nab-Pac**

PDAC safety lead-in: Study summary

<table>
<thead>
<tr>
<th>Dose Level (mg)</th>
<th>Syros-5609 dose (mg)</th>
<th>Number of patients</th>
<th>Dose intensity (mg/kg)</th>
<th>Dose intensity (mg/m²)</th>
<th>B胆 (mg/m²)</th>
</tr>
</thead>
<tbody>
<tr>
<td>2</td>
<td>2</td>
<td>10</td>
<td>0.2</td>
<td>4</td>
<td>4</td>
</tr>
<tr>
<td>5</td>
<td>5</td>
<td>10</td>
<td>0.5</td>
<td>10</td>
<td>10</td>
</tr>
<tr>
<td>10</td>
<td>7</td>
<td>10</td>
<td>0.7</td>
<td>14</td>
<td>14</td>
</tr>
<tr>
<td>15</td>
<td>9</td>
<td>10</td>
<td>0.9</td>
<td>18</td>
<td>18</td>
</tr>
<tr>
<td>20</td>
<td>10</td>
<td>10</td>
<td>1.0</td>
<td>20</td>
<td>20</td>
</tr>
</tbody>
</table>

No DLTs reported

**Background**

* SY-5609 is a highly selective and potent CDK7 inhibitor
* SY-5609 is being investigated as a single agent or in combination with gemcitabine and nab-paclitaxel

**Key Eligibility Criteria**

- Age ≥ 18 years
- Histologically confirmed pancreatic ductal adenocarcinoma (PDAC)
- Karnofsky performance status (KPS) of 50 or greater
- No prior treatment with SY-5609 or gemcitabine/nab-paclitaxel

**Study Objectives**

- Primary: Safety, tolerability, and MTD
- Secondary: Efficacy
- Exploratory: PK and biomarker analyses

**Study Design**

- Phase 1b Study
- Open-label, single-arm
- Multiple dose levels

**Results**

SY-5609 is being evaluated as a single agent or in combination with gemcitabine and nab-paclitaxel. The study is designed to assess the safety, tolerability, and maximum tolerated dose (MTD) of SY-5609 alone or in combination with chemotherapy. The primary endpoint is the occurrence of dose-limiting toxicities (DLTs). The study is enrolling patients with advanced pancreatic ductal adenocarcinoma.

**Pharmacokinetics and Pharmacodynamics**

- SY-5609 exposures in combination with chemotherapy are comparable to exposures achieved with single agent SY-5609 exposures.

**Conclusions**

- SY-5609 OS update for single agent, doublet, and triplet

**Acknowledgments and Contact Information**

- Garath Stumpf, Clinical | garath@syros.com

**References**

- Olatunji B. Alese, Juric D, Farber Cancer Institute, Boston, MA; ASCO Annual Meeting 2012
- Tanya Abdul Malak, Syros Pharmaceuticals, Cambridge, MA; ASCO Annual Meeting 2012
- Michael Kelly, Farber Cancer Institute, Boston, MA; ASCO Annual Meeting 2012
- Tanya Abdul Malak, Syros Pharmaceuticals, Cambridge, MA; ASCO Annual Meeting 2012

**Image**

- [Image of study design and patient enrollment](Image link for study design)

- [Image of pharmacokinetic profile](Image link for pharmacokinetic profile)